Vitamin D Supplementation and Disease Activity in Patients with Immune-mediated Rheumatic Diseases: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Jun 8

PMID 28591033

Citations 42

Authors

Andre Silva Franco

Thiago Quadrante Freitas

Wanderley M Bernardo

Rosa Maria R Pereira

Affiliations

Soon will be listed here.

Abstract

Background: Vitamin D serum levels and the presence and activity of rheumatic conditions have been associated. However, many studies are merely observational, and the existent randomized clinical trials were never systematically analyzed. Therefore, this study aims to provide a systematic review and meta-analysis of such a topic.

Methods: MEDLINE, EMBASE, LILACS, COCHRANE, and CINAHL were explored to identify randomized trials that investigated clinical repercussions of vitamin D (or analogs) supplementation for at least 3 months in rheumatic diseases. Standardized clinical and/or laboratorial outcomes related to disease activity were analyzed according to each disease before and after supplementation.

Results: Database searches rendered 668 results; 9 were included-5 on rheumatoid arthritis, 3 on systemic lupus erythematosus, and 1 on systemic sclerosis. Seven of the studies were meta-analyzed. After vitamin D supplementation, rheumatoid arthritis recurrence decreased; however, not significantly (risk difference = -0.10, 95% CI = -0.21, 0.00, P = .05). No statistical significance was observed regarding visual analog scale (mean difference = 2.79, 95% CI = -1.87, 7.44, P = .24) and disease activity score28 (mean difference = -0.31, 95% CI = -0.86, 0.25, P = .28). Regarding systemic lupus erythematosus, anti-dsDNA positivity was significantly reduced (risk difference = -0.10, 95% CI = -0.18, -0.03; P = .005).

Conclusion: Vitamin D supplementation reduced anti-dsDNA positivity on systemic lupus erythematosus and could possibly reduce rheumatoid arthritis recurrence, although novel randomized clinical trials are needed to confirm and extend the benefits of this hormone in immune-mediated rheumatic diseases.

Citing Articles

The immunomodulatory potential of vitamin D on Th17 lymphocytes in systemic lupus erythematosus - a literature review.

Predescu O, Dinescu S, Bita C, Florescu A, Musetescu A, Vreju F Med Pharm Rep. 2025; 98(1):13-20.

PMID: 39949914 PMC: 11817589. DOI: 10.15386/mpr-2752.

Serum 25-Hydroxyvitamin D Levels and Disease Activity in Patients with Systemic Lupus Erythematosus: An Exploratory Study in Western Mexico.

Deossa-Piedrahita D, Vicente-Hernandez B, Ramirez-Ochoa S, Ambriz-Alarcon M, Cervantes-Perez G, Cervantes-Guevara G Diseases. 2024; 12(12.

PMID: 39727649 PMC: 11726911. DOI: 10.3390/diseases12120319.

The Interconnection Between Systemic Lupus Erythematosus and Diet: Unmet Needs, Available Evidence, and Guidance-A Patient-Driven, Multistep-Approach Study.

Sciascia S, Ferrara G, Roccatello L, Rubini E, Foddai S, Radin M Nutrients. 2024; 16(23).

PMID: 39683527 PMC: 11643781. DOI: 10.3390/nu16234132.

Cytoplasmic DNA and AIM2 inflammasome in RA: where they come from and where they go?.

Xu C, Jing W, Liu C, Yuan B, Zhang X, Liu L Front Immunol. 2024; 15:1343325.

PMID: 39450183 PMC: 11499118. DOI: 10.3389/fimmu.2024.1343325.

When and How to Evaluate Vitamin D Status? A Viewpoint from the Belgian Bone Club.

Lapauw B, Laurent M, Rozenberg S, Body J, Bruyere O, Gielen E Nutrients. 2024; 16(15).

PMID: 39125269 PMC: 11313844. DOI: 10.3390/nu16152388.

References

Ding Y, Liao W, He X, Xiang W . Effects of 1,25(OH) D and vitamin D receptor on peripheral CD4 /CD8 double-positive T lymphocytes in a mouse model of systemic lupus erythematosus. J Cell Mol Med. 2017; 21(5):975-985. PMC: 5387123. DOI: 10.1111/jcmm.13037. View

Nikpour M, Urowitz M, Ibanez D, Gladman D . Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009; 61(9):1152-8. DOI: 10.1002/art.24741. View

Joshi S, Pantalena L, Liu X, Gaffen S, Liu H, Rohowsky-Kochan C . 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011; 31(17):3653-69. PMC: 3165548. DOI: 10.1128/MCB.05020-11. View

Floris A, Piga M, Cauli A, Mathieu A . Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev. 2016; 15(7):656-63. DOI: 10.1016/j.autrev.2016.02.019. View

Hsu H, Yang P, Wang J, Wu Q, Myers R, Chen J . Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2007; 9(2):166-75. DOI: 10.1038/ni1552. View

Marinho A, Taveira M, Vasconcelos C . Topics on vitamin D in systemic lupus erythematosus: analysis of evidence and critical literature review. Immunol Res. 2017; 65(2):495-511. DOI: 10.1007/s12026-017-8903-5. View

Durcan L, Petri M . Immunomodulators in SLE: Clinical evidence and immunologic actions. J Autoimmun. 2016; 74:73-84. PMC: 5079835. DOI: 10.1016/j.jaut.2016.06.010. View

Jackson R, LaCroix A, Gass M, Wallace R, Robbins J, Lewis C . Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006; 354(7):669-83. DOI: 10.1056/NEJMoa055218. View

Lin J, Liu J, Davies M, Chen W . Serum Vitamin D Level and Rheumatoid Arthritis Disease Activity: Review and Meta-Analysis. PLoS One. 2016; 11(1):e0146351. PMC: 4709104. DOI: 10.1371/journal.pone.0146351. View

10.

Grossman J, Gordon R, Ranganath V, Deal C, Caplan L, Chen W . American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010; 62(11):1515-26. DOI: 10.1002/acr.20295. View

11.

Jeffery L, Raza K, Hewison M . Vitamin D in rheumatoid arthritis-towards clinical application. Nat Rev Rheumatol. 2015; 12(4):201-10. DOI: 10.1038/nrrheum.2015.140. View

12.

Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow M . A surge in anti-dsDNA titer predicts a severe lupus flare within six months. Lupus. 2013; 23(3):293-8. DOI: 10.1177/0961203313515763. View

13.

Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S . Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999; 5(2):101-4. DOI: 10.1177/135245859900500206. View

14.

Cantorna M . Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc. 2010; 69(3):286-9. PMC: 3138329. DOI: 10.1017/S0029665110001722. View

15.

Pentek M, Poor G, Wiland P, Olejarova M, Brzosko M, Codreanu C . Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ. 2014; 15 Suppl 1:S35-43. DOI: 10.1007/s10198-014-0592-6. View

16.

Gatenby P, Lucas R, Swaminathan A . Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol. 2013; 25(2):184-91. DOI: 10.1097/BOR.0b013e32835cfc16. View

17.

Salesi M, Farajzadegan Z . Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. Rheumatol Int. 2011; 32(7):2129-33. DOI: 10.1007/s00296-011-1944-5. View

18.

Hulshof M, Bouwes Bavinck J, Bergman W, Masclee A, Heickendorff L, Breedveld F . Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000; 43(6):1017-23. DOI: 10.1067/mjd.2000.108369. View

19.

Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C . Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010; 10(4):482-96. DOI: 10.1016/j.coph.2010.04.001. View

20.

Cantorna M, Hayes C, DeLuca H . 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A. 1996; 93(15):7861-4. PMC: 38839. DOI: 10.1073/pnas.93.15.7861. View